The phase III SELENE trial assessed whether adding ibrutinib to BR or R-CHOP could extend PFS in previously treated patients with R/R FL or MZL. The study’s primary endpoint was investigator-assessed PFS. Secondary endpoints were OS, ORR, CR, DOR, and safety. Adding ibrutinib to CIT demonstrated clinical activity, though the PFS improvement lacked […]...
Trusted insights straight to your inbox and get the latest updates from OncWeekly
Advertisement
Background Immune-related adverse events (irAEs) are major barriers of clinical management and further development of immune checkpoint inhibitors (ICIs) for cancer therapy. Therefore, biomarkers associated with the onset of severe irAEs are needed. In this study, …
Background Adoptive cell transfer (ACT) shows promise as an immunotherapy for melanoma and other cancers. However, there are several challenges associated with ACT such as the logistical complexity and inconsistency when using patient-derived antigen-presenting cells for …
Background Immune checkpoint inhibitors (ICIs) are standard therapy for advanced hepatocellular carcinoma (HCC). However, the efficacy of combining nivolumab and ipilimumab in Anti-PD(L)-1 Naïve and Experienced HCC patients remains unclear. Methods We retrospectively reviewed 23 patients with advanced …
Background Novel early-line therapies for advanced (unresectable or metastatic) melanoma are needed to improve the rate of deep and durable responses and increase the proportion of patients with long-term benefit. TILVANCE-301 will evaluate the efficacy and …
